{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(12)"],"submitter":["Ma TM"],"pubmed_abstract":["<h4>Importance</h4>Novel hormonal therapy (NHT) agents have been shown to prolong overall survival in numerous randomized clinical trials for patients with advanced prostate cancer (PCa). There is a paucity of data regarding the pattern of use of these agents in patients from different racial and ethnic groups.<h4>Objective</h4>To assess racial and ethnic disparities in the use of NHT in patients with advanced PCa.<h4>Design, setting, and participants</h4>This cohort study comprised all men diagnosed with de novo advanced PCa (distant metastatic [M1], regional [N1M0], and high-risk localized [N0M0] per Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy [STAMPEDE] trial criteria) with Medicare Part A, B, and D coverage between January 1, 2011, and Decem"],"journal":["JAMA network open"],"pagination":["e2345906"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10692845"],"repository":["biostudies-literature"],"pubmed_title":["Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer."],"pmcid":["PMC10692845"],"pubmed_authors":["Agarwal N","Spratt D","Kishan AU","Vapiwala N","Garraway I","Steinberg ML","Rettig MB","Ma TM","Mahal B","Valle LF","Xiang M","Barragan-Carrillo R"],"additional_accession":[]},"is_claimable":false,"name":"Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer.","description":"<h4>Importance</h4>Novel hormonal therapy (NHT) agents have been shown to prolong overall survival in numerous randomized clinical trials for patients with advanced prostate cancer (PCa). There is a paucity of data regarding the pattern of use of these agents in patients from different racial and ethnic groups.<h4>Objective</h4>To assess racial and ethnic disparities in the use of NHT in patients with advanced PCa.<h4>Design, setting, and participants</h4>This cohort study comprised all men diagnosed with de novo advanced PCa (distant metastatic [M1], regional [N1M0], and high-risk localized [N0M0] per Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy [STAMPEDE] trial criteria) with Medicare Part A, B, and D coverage between January 1, 2011, and Decem","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2025-04-21T23:12:47.848Z","creation":"2025-04-05T19:01:35.958Z"},"accession":"S-EPMC10692845","cross_references":{"pubmed":["38039002"],"doi":["10.1001/jamanetworkopen.2023.45906"]}}